

You are invited to a  
presentation on **NUPLAZID®**:

ONCE-DAILY  
**NUPLAZID®**  
(pimavanserin) 34mg capsules

See Important Safety Information,  
including **Boxed WARNING** below.

# NUPLAZID: The First-Line Prescription Treatment for Hallucinations and Delusions Associated With Parkinson's Disease Psychosis

## Meeting Details

Thursday, July 24, 2025  
6:30 PM EST  
**Ruth's Chris Steakhouse**  
Volunteer Room  
950 Volunteer Landing Lane  
Knoxville, TN 37915  
865-546-4696

## Presented by



Paid consultant  
of Acadia  
Pharmaceuticals Inc.

### Fahd S. Amjad, MD

Assistant Professor  
Department of Neurology, Division of Movement Disorders  
Co-Director  
Huntington's Disease Center of Excellence  
Georgetown University Hospital  
Washington, DC

## Presentation Objectives

- Learn more about the prevalence and impact of hallucinations and delusions associated with Parkinson's disease (PD) psychosis, and the importance of routine screening
- Examine the therapeutic bind when managing both the motor and nonmotor symptoms of PD
- Explore the clinical efficacy data and the safety profile of NUPLAZID, the first and only FDA-approved treatment for hallucinations and delusions associated with PD psychosis
- Review the support provided by Acadia Connect® to help patients start and continue on NUPLAZID

## Space is limited, so register now.

Enter 303166 at  
<https://AcadiaPrograms.com>  
Online registration is preferred.

You may also contact  
Brian Johnson  
423-426-2208  
[Brian.Johnson@Acadia-Pharm.com](mailto:Brian.Johnson@Acadia-Pharm.com).



Please note: This program is subject to cancellation.  
Use the link above or scan the QR Code with your device.

## Indication

NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

## Important Safety Information

### **WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS**

- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
- NUPLAZID is not approved for the treatment of patients with dementia who experience psychosis unless their hallucinations and delusions are related to Parkinson's disease.

See additional Important Safety Information located on reverse. Please read the accompanying full [Prescribing Information](#), including Boxed WARNING, also available at [NUPLAZIDhcp.com](https://www.acadia-pharm.com/NUPLAZIDhcp).

## Important Safety Information (cont'd)

**Contraindication:** NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.

### Warnings and Precautions: QT Interval Prolongation

- NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval (e.g., Class 1A antiarrhythmics, Class 3 antiarrhythmics, certain antipsychotics or antibiotics).
- NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

**Adverse Reactions:** The adverse reactions ( $\geq 2\%$  for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs  $<1\%$ ).

### Drug Interactions:

- Coadministration with strong CYP3A4 inhibitors increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.
- Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.

### Dosage and Administration

Recommended dose: 34 mg capsule taken orally once daily, without titration, with or without food.

NUPLAZID is available as 34 mg capsules and 10 mg tablets.

Please read the accompanying full [Prescribing Information](#), including Boxed WARNING, also available at [NUPLAZIDhcp.com](#).

#### Speaker Program Guidelines

A meal may be offered. Alcohol will not be provided.

Acadia Pharmaceuticals is pleased to sponsor this program to provide information consistent with industry guidelines. This program is not an accredited CME program and is not designed to meet any training and/or educational requirements. In accordance with the PhRMA Code on Interactions With Health Care Professionals, attendance at this educational program is limited to only Health Care Professionals (Physicians, Nurse Practitioners, Physician Assistants, RNs, Clinical Pharmacists, Social Workers). Accordingly, attendance by guests or spouse is not permitted.

To comply with certain federal, state, and local laws that prohibit or limit the provision of meals to health care professionals and/or state employees, Acadia Pharmaceuticals does not offer a complimentary meal to individuals who are subject to such restrictions. Attendees to whom such restrictions apply should not avail themselves of the complimentary meal. Please note that Acadia Pharmaceuticals is required to report the value of a provided meal pursuant to applicable federal and state laws.

This invitation is non-transferrable.

[Privacy Policy](#)